SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Success roadmap journey, milestone or career path achievement, route or pathway to achieve goals, accomplishment, assessment or way to success, businessman look at achievement milestone to success.
GLP-1
Novo Paints Murky Cardio Picture for Semaglutide Franchise
According to BMO Capital Markets, Rybelsus’ outcomes in SOUL were “inconsistent,” failing to significantly lower cardiovascular death and nonfatal stroke.
March 31, 2025
 · 
2 min read
 · 
Tristan Manalac
Digits abstract background with connected line and dots, wave flow. Digital neural networks. Network and connection background for your presentation.
IN PARTNERSHIP WITH ECLIPSEBIO
Beyond Black Box: How Data-Driven AI Is Transforming RNA Medicine Development
AI offers tremendous potential but there are critical and time-consuming flaws in black box AI predictions.
March 31, 2025
 · 
7 min read
 · 
BioSpace Insights
Photo of attendees at the “Investor and Market Insights” panel at the 2025 Cell & Gene Therapy Summit
IN PARTNERSHIP WITH CHARLES RIVER LABORATORIES
Cell and Gene Therapy Sector Sees 30% Investment Surge Despite Market Challenges
Industry updates and investment insights—including investor behavior and fundraising advice—were among the topics experts explored at Charles River Laboratories’ 2025 Cell & Gene Therapy Summit.
March 31, 2025
 · 
5 min read
 · 
BioSpace Insights
Michelle Werner
People
For Alltrna CEO Michelle Werner, Making Better Drugs Is Personal
Werner held roles at Bristol Myers Squibb, AstraZeneca and Novartis before landing at Alltrna, where she works to develop tRNA-based treatments for a range of diseases.
March 31, 2025
 · 
5 min read
 · 
Shawna Williams
3d rendering of Radiopharmaceuticals, these are radioactive medications or radioisotopes. These medications can be delivered orally in pill form.
Radiopharmaceuticals
5 Big Pharmas Push Boundaries in Radiopharmaceuticals
While Novartis and Bayer got there first, AstraZeneca, Bristol Myers Squibb and Eli Lilly are all vying to bring their radiopharmaceutical assets to a market projected to be worth over $13 billion by 2033.
March 31, 2025
 · 
9 min read
 · 
Tristan Manalac
A scientist with pill bottles in front of FDA headquarters
Regulatory
FDA Action Alert: Amgen, Aldeyra and Argenx
In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.
March 31, 2025
 · 
3 min read
 · 
Tristan Manalac
Wooden blocks with arrow and error icon. Delays and disruptions, stop the process, critical error concept
Alzheimer’s disease
EU Rejects Lilly’s Alzheimer’s Drug Kisunla, Following Same Path as Rival Leqembi
The European Union’s CHMP said that the benefits of the drug, already approved in the U.S., do not outweigh the risk of potentially fatal brain swelling and bleeding.
March 28, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Contemporary art collage. Conceptual image. Businessman catching money given by a hand. In search of profit. Concept of business, economy, financial growth, promotion, following
Obesity
‘There’s Only One Semaglutide’: Novo CEO Admits Compounders Are Hurting Weight Loss Business
Compounded versions could make up as much as 40% of the semaglutide market, said Novo Nordisk CEO Lars Fruergaard Jorgensen on Thursday, but the company hopes to win patients over.
March 28, 2025
 · 
1 min read
 · 
Annalee Armstrong
Heart rate cardiogram, heart rate indicators, EKG monitoring, electrocardiogram. The illustration is in red colors and the background is dark red with a grid.
Complete response letters
Milestone Stock Crashes After Surprise Tachycardia Drug Rejection
Milestone Pharmaceuticals hit another bump in the road in its quest to get Cardamyst approved for paroxysmal supraventricular tachycardia when the FDA issued a Complete Response Letter on Friday.
March 28, 2025
 · 
2 min read
 · 
Heather McKenzie
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS